DRG Market Assessment reports

Biomarker-driven prescribing is entrenched in indications such as non-small-cell lung cancer (NSCLC) and malignant melanoma and is playing an increasingly important role in indications such as…

Treatment Sequencing provides disease-specific, sequential treatment patterns in market-relevant treatment scenarios and drug share mapped to the treatment journey. The quantitative sequencing…

The malignant melanoma market has become increasingly crowded in recent years with novel treatments expanding therapy options for patients and segmenting the market according to BRAF mutational…

The malignant melanoma therapy market is emerging from a very dynamic period (notably 2011-2015) characterized by a plethora of new drug approvals and label expansions. The approvals of both immune…

Immune checkpoint inhibitors (ICIs), including Bristol-Myers Squibb’s Opdivo and Yervoy and Merck & Co.’s Keytruda, are revolutionizing the therapeutic strategies for several cancers, notably…

Immune checkpoint inhibitors have revolutionized the treatment of multiple oncology indications but the high costs associated with these agents present significant challenges for payers. The…

Biomarker-targeted therapies are distinguished from other oncology drugs in that they are accompanied by a diagnostic test that can identify a specific patient type most likely to benefit from…

Treatment of BRAF-mutation-positive unresectable or metastatic malignant melanoma has been transformed in recent years by the identification of BRAFmutations and the development of BRAF and MEK…

Treatment Sequencing provides disease-specific, sequential treatment patterns in market-relevant treatment scenarios and drug share mapped to treatment journey. The quantitative sequencing analysis…

Treatment Sequencing provides disease-specific, sequential treatment patterns in market-relevant treatment scenarios and drug share mapped to treatment journey. The quantitative sequencing analysis…

Immune checkpoint inhibitors have entered multiple oncology indications but the high costs associated with these agents present significant challenges for payers. The potential for label expansions…

The malignant melanoma treatment landscape is dynamic and continues to undergo significant changes. Three immune checkpoint inhibitors including a dual checkpoint blockade regimen, four BRAF or MEK…